VAERS reports by lot

GSK Varicella/Shingles lot 252JX: VAERS reports

28 VAERS reports list lot 252JX as a GSK Varicella/Shingles vaccine, received between 2022-07-12 and 2023-10-30. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
28
Reports
4%
Marked serious
0
With a death outcome
10
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
Injection-site / Local reaction3133%
Dermatological (non-injection-site)1314%
General / Systemic (non-local)1314%
Cardiac / Cardiovascular1213%
Neurological88%
Musculoskeletal77%
Gastrointestinal55%
Respiratory33%
Allergic / Anaphylactic22%
Thrombotic / Hematological11%

Where reports came from

U.S. state of the reporter, where given (top 12).

Pennsylvania4
Colorado4
Tennessee2
Oregon2
Texas2
Alabama1
Washington1
Kansas1
South Carolina1
New Jersey1
New York1
Massachusetts1

Reports by month received

2022-073
2022-086
2022-095
2022-107
2023-011
2023-031
2023-051
2023-081
2023-091
2023-102

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.